I looked at the slide deck again to make sure. There was a slide headed with,

BETonMACE2 Estimated to cost $30 - $35 million for Resverlogix

He stated:

"We have an agreement with our partners in Asia that they will be funding half of this trial and we will pick up the balance."

The slide also said,

Clinical Cost Est: $60-$70 million with a pie chart showing, Hepalink up to 50% and RVX 50%+

So overruns are covered by RVX. It would be nice if they loaded this slide deck onto the website.